Review



alimta  (Eli Lilly)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Eli Lilly alimta
    Alimta, supplied by Eli Lilly, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pemetrexed/us12655159-436-11-12?v=Eli+Lilly
    Average 86 stars, based on 1 article reviews
    alimta - by Bioz Stars, 2026-07
    86/100 stars

    Images



    Similar Products

    pemetrexed  (MedChemExpress)
    93
    MedChemExpress pemetrexed
    Pemetrexed, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pemetrexed/10__1016_slash_j__ijpx__2026__100558-58-0-4?v=MedChemExpress
    Average 93 stars, based on 1 article reviews
    pemetrexed - by Bioz Stars, 2026-07
    93/100 stars
    		  Buy from Supplier
    alimta  (Eli Lilly)
    86
    Eli Lilly alimta
    Alimta, supplied by Eli Lilly, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pemetrexed/us12655159-436-11-12?v=Eli+Lilly
    Average 86 stars, based on 1 article reviews
    alimta - by Bioz Stars, 2026-07
    86/100 stars
    		  Buy from Supplier
    mta  (Dentsply Sirona)
    86
    Dentsply Sirona mta
    Mta, supplied by Dentsply Sirona, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pemetrexed/pmc13266017-66-38-41?v=Dentsply+Sirona
    Average 86 stars, based on 1 article reviews
    mta - by Bioz Stars, 2026-07
    86/100 stars
    		  Buy from Supplier
    proroot mta  (Dentsply Sirona)
    86
    Dentsply Sirona proroot mta
    Proroot Mta, supplied by Dentsply Sirona, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pemetrexed/pm42159272-165-4-6?v=Dentsply+Sirona
    Average 86 stars, based on 1 article reviews
    proroot mta - by Bioz Stars, 2026-07
    86/100 stars
    		  Buy from Supplier
    pemetrexed  (Eli Lilly)
    86
    Eli Lilly pemetrexed
    Overall Survival (OS) of patients with Leptomeningeal Metastasis (LM) from the whole cohort and Kaplan–Meier estimates based on clinical characteristics. A The median OS (mOS) of all the patients after diagnosis of LM was 8.0 months. B Patients with high Karnofsky Performance Status scores had better mOS (> 60 versus ≤ 60: 9.0 versus 5.0 months, hazard ratio [HR]: 0.60, P = 0.005). C Patients who had extensive systemic disease with few treatment options had slightly higher mOS (8.0 versus 6.0 months, HR: 0.65, P = 0.014). D Patients who received more than six times of intrathecal <t>pemetrexed</t> (IP) had better mOS (> 6 versus ≤ 6: 14.0 versus 5.0 months, HR: 0.41, P < 0.001). E Patients with response for IP treatment had better mOS (effective versus non-effective: 8.0 versus 4.0 months, HR: 0.50, P < 0.001). F Continued negative cerebrospinal fluid cytology after treatment was associated with longer survival (mOS 11.0 versus 5.0 months, HR: 0.42, P < 0.001)
    Pemetrexed, supplied by Eli Lilly, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pemetrexed/pmc13192031-183-0-2?v=Eli+Lilly
    Average 86 stars, based on 1 article reviews
    pemetrexed - by Bioz Stars, 2026-07
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    Overall Survival (OS) of patients with Leptomeningeal Metastasis (LM) from the whole cohort and Kaplan–Meier estimates based on clinical characteristics. A The median OS (mOS) of all the patients after diagnosis of LM was 8.0 months. B Patients with high Karnofsky Performance Status scores had better mOS (> 60 versus ≤ 60: 9.0 versus 5.0 months, hazard ratio [HR]: 0.60, P = 0.005). C Patients who had extensive systemic disease with few treatment options had slightly higher mOS (8.0 versus 6.0 months, HR: 0.65, P = 0.014). D Patients who received more than six times of intrathecal pemetrexed (IP) had better mOS (> 6 versus ≤ 6: 14.0 versus 5.0 months, HR: 0.41, P < 0.001). E Patients with response for IP treatment had better mOS (effective versus non-effective: 8.0 versus 4.0 months, HR: 0.50, P < 0.001). F Continued negative cerebrospinal fluid cytology after treatment was associated with longer survival (mOS 11.0 versus 5.0 months, HR: 0.42, P < 0.001)

    Journal: BMC Cancer

    Article Title: Real-world evidence for first-line intrathecal pemetrexed in leptomeningeal metastases from solid tumors: a retrospective cohort study

    doi: 10.1186/s12885-026-15915-5

    Figure Lengend Snippet: Overall Survival (OS) of patients with Leptomeningeal Metastasis (LM) from the whole cohort and Kaplan–Meier estimates based on clinical characteristics. A The median OS (mOS) of all the patients after diagnosis of LM was 8.0 months. B Patients with high Karnofsky Performance Status scores had better mOS (> 60 versus ≤ 60: 9.0 versus 5.0 months, hazard ratio [HR]: 0.60, P = 0.005). C Patients who had extensive systemic disease with few treatment options had slightly higher mOS (8.0 versus 6.0 months, HR: 0.65, P = 0.014). D Patients who received more than six times of intrathecal pemetrexed (IP) had better mOS (> 6 versus ≤ 6: 14.0 versus 5.0 months, HR: 0.41, P < 0.001). E Patients with response for IP treatment had better mOS (effective versus non-effective: 8.0 versus 4.0 months, HR: 0.50, P < 0.001). F Continued negative cerebrospinal fluid cytology after treatment was associated with longer survival (mOS 11.0 versus 5.0 months, HR: 0.42, P < 0.001)

    Article Snippet: Pemetrexed (Alimta, Eli Lilly and Company, 100 mg) was dissolved in a 0.9% sodium chloride solution (3–5 mL) and prepared into a 50-mL mixture.

    Techniques: Biomarker Discovery

    The Overall Survival (OS) of patients with Leptomeningeal Metastasis (LM) from the Non-Small-Cell Lung Cancer (NSCLC) cohort and Kaplan–Meier estimates based on clinical characteristics. A The median OS (mOS) of all the patients after diagnosis of leptomeningeal metastasis (LM) was 6.0 months. B Patients with local treatment had better mOS (8.0 versus 3.0 months, hazard ratio [HR]: 0.58, P = 0.023). C Patients who received more than six times of intrathecal pemetrexed (IP) had better mOS (> 6 versus ≤ 6: 16.0 versus 4.0 months, HR: 0.33, P < 0.001). D Patients with response for IP treatment had better mOS (effective versus non-effective: 11.0 versus 3.5 months, HR: 0.46, P < 0.001). E Continued negative cerebrospinal fluid cytology after treatment was associated with longer survival (mOS 12.0 versus 4.0 months, HR: 0.41, P < 0.001)

    Journal: BMC Cancer

    Article Title: Real-world evidence for first-line intrathecal pemetrexed in leptomeningeal metastases from solid tumors: a retrospective cohort study

    doi: 10.1186/s12885-026-15915-5

    Figure Lengend Snippet: The Overall Survival (OS) of patients with Leptomeningeal Metastasis (LM) from the Non-Small-Cell Lung Cancer (NSCLC) cohort and Kaplan–Meier estimates based on clinical characteristics. A The median OS (mOS) of all the patients after diagnosis of leptomeningeal metastasis (LM) was 6.0 months. B Patients with local treatment had better mOS (8.0 versus 3.0 months, hazard ratio [HR]: 0.58, P = 0.023). C Patients who received more than six times of intrathecal pemetrexed (IP) had better mOS (> 6 versus ≤ 6: 16.0 versus 4.0 months, HR: 0.33, P < 0.001). D Patients with response for IP treatment had better mOS (effective versus non-effective: 11.0 versus 3.5 months, HR: 0.46, P < 0.001). E Continued negative cerebrospinal fluid cytology after treatment was associated with longer survival (mOS 12.0 versus 4.0 months, HR: 0.41, P < 0.001)

    Article Snippet: Pemetrexed (Alimta, Eli Lilly and Company, 100 mg) was dissolved in a 0.9% sodium chloride solution (3–5 mL) and prepared into a 50-mL mixture.

    Techniques: Biomarker Discovery